A Study to Learn How Different Forms of the Study Medicine Called PF 08049820 Are Taken up Into the Bloodstream in Healthy Adults

NCT ID: NCT07172321

Last Updated: 2025-11-17

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 12 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-09-05
• Study Completion Date: 2025-10-29

Brief Summary

The purpose of this study is to see how different forms of a medicine called PF-08049820 move through the body when taken by mouth. The scientists want to see:

• How well is the medicine absorbed when it's made in different ways (fast vs. slow release)
• If eating a high-fat meal changes how the medicine moves through the body The results of this study will help decide which version of the medicine is best for future studies.

This study is seeking participants who:

• are men and women who can't have children
• are 18 years or older
• weigh more than 99 pounds (45 kg)
• have a healthy body weight (not too low or too high)
• are generally healthy with no serious medical problems. People with serious health problems, recent drug use, or who had certain vaccines recently cannot join.
• are willing to follow all the study rules

Each participant will try 5 different versions of the medicine, one at a time. There will be 3 days between each dose to make sure the medicine is out of the system. The medicine will be tested in different forms:

• Immediate-release tablet (works quickly)
• Short-release tablet (works slowly)
• Long-release tablet (works even slower)

Some versions will be taken without food, and others after eating a high-fat meal. After each dose, doctors will take blood samples for up to 72 hours to see how the medicine moves through the body. The whole study will take about 6 to 11 weeks and participants will stay overnight in the clinic for about 17 days.

Conditions

Atopic Dermatitis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

Treatment A

Participants will receive a single dose of PF-08049820 short Modified release (MR) release rate (MR1) tablets under fasted conditions.

Group Type: EXPERIMENTAL

PF-08049820 MR1

Intervention Type: DRUG

Administered orally

Treatment B

Participants will receive a single dose of PF-08049820 long MR release rate (MR2) tablets under fasted conditions.

Group Type: EXPERIMENTAL

PF-08049820 MR2

Intervention Type: DRUG

Administered orally

Treatment C

Participants will receive a single dose of PF-08049820 Immediate Release (IR) tablets under fasted conditions.

Group Type: EXPERIMENTAL

PF-08049820 IR

Intervention Type: DRUG

Administered orally

Treatment D

Participants will receive a single dose of PF-08049820 MR2 tablets under fed conditions.

Group Type: EXPERIMENTAL

PF-08049820 MR2

Intervention Type: DRUG

Administered orally

Treatment E

Participants will receive a single dose of PF-08049820 IR tablets under fed conditions.

Group Type: EXPERIMENTAL

PF-08049820 IR

Intervention Type: DRUG

Administered orally

Interventions

PF-08049820 MR1

Administered orally

Intervention Type: DRUG

PF-08049820 MR2

Administered orally

Intervention Type: DRUG

PF-08049820 IR

Administered orally

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Male and female participants of non-childbearing potential ≥18 years of age
• BMI of 16-32 kg/m2; and a total body weight >45 kg (99 lbs)
• Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion Criteria

• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).

• Any condition possibly affecting drug absorption (eg, gastrectomy, cholecystectomy).
• History of HIV infection, hepatitis B, or hepatitis C; positive testing for HIV, HBsAg, HBsAb, HBcAb, or HCVAb. A positive HBsAb result and a history of Hepatitis B vaccination is allowed.
• Use of certain prescription or nonprescription drugs and dietary (e.g. grapefruit) and herbal supplements within up to 14 days or 5 half-lives, whichever is longer, prior to the first dose of study intervention.
• Recent exposure to live or attenuated vaccines within 28 days of the screening visit.
• Previous administration of an investigational product (drug or vaccine) within 30 days or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer).
• History of alcohol abuse or repeated binge drinking and/or any other illicit drug use or dependence within 6 months of screening.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Pfizer

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Pfizer Clinical Research Unit - New Haven

New Haven, Connecticut, United States

Countries

United States

Related Links

https://pmiform.com/clinical-trial-info-request?StudyID=C6231007

To obtain contact information for a study center near you, click here.

Other Identifiers

C6231007

Identifier Type: -

Identifier Source: org_study_id